Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of lavender oil WS 1265 in generalized anxiety disorder
2005-004474-25Phase 2Completed
- Sponsor
- Schwabe Group
- Start
- Jan 2006
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Silexan in generalized anxiety disorder (GAD) (4 arms), sponsored by Schwabe Group. Primary endpoint: Change in HAM-A total score from baseline to end of treatment. Started Jan 2006; status: completed.
02
Drugs
Silexan
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2005-004474-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004474-25.